Clinical Trial Update: Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer

View source ↗

Summary

Completed clinical trial evaluating soluble VEGF receptor 2 as a biomarker to predict benefit from continuing bevacizumab beyond progression in metastatic color…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Azienda Ospedaliero, Universitaria Pisana | Conditions: Metastatic Colorectal Cancer | Status: COMPLETED